39-301: Special Drug Use-Results Survey of DEMSER

39-301: Special Drug Use-Results Survey of DEMSER (Improvement of catecholamine hypersecretion in pheochromocytoma)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2031240474

Enrollment

250

Registered

2024-11-08

Start date

2019-06-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pheochromocytoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have recieved DEMSER for improvement of catecholamine hypersecretion in pheochromocytoma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Safety items : Occurrence of adverse drug reactions and infections, factors considered to influence the safety Efficacy items : Overall improvement, metanephrines fractionation (24-hour urine collection, spot urine, free), catecholamines 3 fractionation (24-hour urine collection, spot urine, plasma), factors considered to influence the efficacy	—

Contacts

Public ContactTakafumi Nakao

Ono Pharmaceutical Co.,LTD

pms_contact_ml@ono-pharma.com+81-6-6222-5501

Outcome results